New Hope Network is part of the Informa Markets Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Tempo Carries Genesis Soft Chews and Powdered Oils

Source: NHP Report

Genesis Research Corporation of Lake Bluff, USA, a leader in providing marketable unique formulations and novel processing technologies has come up with an innovative alternative to traditional encapsulated products which is now available for Canadian manufacturers. For consumers who have difficulty in swallowing traditional encapsulated or softgel products, Genesis Soft Chews make getting the daily dose of vitamins, minerals and botanicals easy. “The secret is to focus first on developing a great-tasting soft chew candy, then enrich it with vitamins, minerals or other herbals,” says William Smart, General Manager, Genesis Research Corporation.

Genesis Soft Chews are available in bulk, pre-packaged tubs, or other customer-supplied containers. The line includes: Cal 3™ Calcium chews (a blend of calcium and vitamins D and K); Flex™ Joint chews formulated to help maintain joint health and flexibility and available in a single ingredient, glucosamine, or a blend of glucosamine, chondroitin and MSM; Creatine chews, Vitamin C chews; Multivitamin chews containing 24 essential vitamins and minerals; and, Genesis All Naturals™ chews containing only natural vitamins, minerals, sweeteners and flavourings.

For children, Genesis Research Corporation has KidsCare Fruit Chews, a gummy-candy chew which meets or exceeds the recommended daily RDI for vitamin C. These all-natural chews contain no artificial colors, flavors, preservatives, and there are no starchy fillers or binders. “KidsCare chews can help assure that children get an adequate amount of Vitamin C on a daily basis. Unlike many other chewable products, KidsCare chews offer the long-lasting real fruit flavor and the gummy-candy form that appeals to children,” says William Smart, General Manager, Genesis Research Corporation.

Genesis which is known in the U.S. for its numerous breakthrough products as well as improvements to some of the most popular formulations or finished products is confident that Canadians will take to their soft chews for either functional food or nutraceutical applications.

For information and product specs, contact their Canadian distributor, Tempo Canada, Inc. at 1-800-622-5009 or e-mail at [email protected]..

Tempo Carries Genesis Powdered Oils
Genesis Research Corporation of Lake Bluff, USA, a provider of popular dietary supplements, nutrients and technologies is revolutionizing nutracuetical manufacturing and functional food processing with its new, all-natural oil-to-powder production process using no non-synthetic polymers.

According to William Smart of Genesis, “Compared to other technologies such as fluid bed or Wurster column it offers significant benefits. First, it produces a fine free-flowing powder with yields of 95 to 99% of the powder’s original active ingredients. Second, it stabilizes the oil and masks taste. Third, our proprietary process accomplishes this at a fraction of the cost of existing methods.” Other benefits include stabilization and protection of oil’s active ingredients from the harsh pH environment of the stomach, for use as a delivery mechanism to the lower gastrointestinal tract.

“This technology enables us to produce a high-yield powder that is suitable for use in drink mixes, nutrition bars, smoothies and other beverages, or other food additives, as well as in traditional applications in hard shell encapsulation,” Smart added.

Genesis’ Ten-30 line of oil powders includes: borage, canola, castor, cod liver eveningprimrose, fish, flaxseed (organic/non-organic), olive, oregano, pumpkin, salmon, vitamin E.

For information and product specs on the Genesis’ Ten-30™ line of edible oil powders, contact Tempo Canada Inc. at 1-800-622-5009 or e-mail to [email protected].

 

Pharmanex Creates a New Reference Tool to Help Elite Athletes and Trainers Identify Prohibited Substances Used in Some Dietary Supplements

Guide Examines Five Most Prevalent 'Banned' Ingredients Found in Sports Supplements and Over-the-Counter Products Available to Athletes

January 2002 (Newstream) -- Pharmanex has announced the availability of a guide to help clarify issues surrounding appropriate dietary supplementation and unintentional doping in sports. This guide is especially timely, as athletes finish preparations for imminent world-level competition.

The brochure, titled "Athletes' Guide to Safe Supplementation," was not designed to be an exhaustive examination of all ingredients banned within the international sports community. Instead, the piece examines five classes of prohibited ingredients commonly found in dietary sports supplements and over-the-counter (OTC) products. By educating athletes about the issue of banned substances, Pharmanex hopes to reduce the risk of athletes using dietary supplements that could trigger a positive doping test. The guide is available at no charge to athletic organizations and media by calling (801) 345-2044.

Through its affiliation with elite sports organizations, and as a provider of dietary supplements, Pharmanex is keenly aware of the confusion surrounding the issue of appropriate dietary supplementation and unintentional doping. Pharmanex has a strict policy of not using any ingredients prohibited in international athletic competition. Pharmanex has also tested all of its products at independent labs to ensure no banned substances were inadvertently introduced during the manufacturing process. However, Pharmanex recognizes that athletes may need more information about products that do contain these substances. Much of the confusion relates to ingredients in supplements and OTC products that are legal for sale in the United States, but are prohibited for use by athletes involved in world-class competition.

"By concentrating on the ingredients that athletes commonly come in contact with, we felt our brochure would help shed additional light on a confusing subject," said Joe Chang, Ph.D., president of Pharmanex. "We know that athletes sometimes unknowingly use products that could cause a positive doping test, but they may also be shying away from effective dietary supplements that are free of banned substances. Clear guidance on this issue is hard to find-this guide is a first step in providing the information necessary to make informed decisions," concluded Chang.

The brochure examines five popular ingredients prohibited in international competition: DHEA, androstenedione, ephedrine, caffeine and synephrine. Classified as stimulants and anabolic agents, these ingredients are prevalent in products that help manage weight, relieve common cold symptoms, boost energy/reduce fatigue and increase muscle strength.

The brochure identifies the ingredients' scientific names, notes whether they constitute a health risk and/or provide an unfair competitive advantage, and gives a sampling of products currently on the market that contain these prohibited substances. The guide also describes why, though available for sale legally, these ingredients are banned for use by athletes engaged in world-level competition. It also focuses on common questions asked about dietary supplements, in an effort to dispel popular myths and provide critical education.

"It is great that Pharmanex is taking extra steps to insure the quality of their products," said Alan Ashley, Athletic Director of the U.S. Ski & Snowboard Association. "There is a lot of controversy about the contents of dietary supplements and the lack of regulations. In this case, however, Pharmanex has not only taken the extra steps needed to identify the components of its products, but has also attempted to provide educational assistance to athletes."

Pharmanex, a Nu Skin Enterprises' company (NYSE: NUS), is a leader in research and development of phyto-pharmaceutical and nutritional products. The company has a portfolio of multivitamin/mineral supplements, natural health products, standardized botanicals and specialized health systems. Based in Provo, Utah, Pharmanex products are sold direct to the consumer through the Internet and a network of independent representatives. For additional information, call (800) 487-1000 or visit the company's Web site at www.pharmanex.com

Cyanotech Japan YK Formed to Service Growing Market Demand

KAILUA-KONA, Hawaii--Jan. 24, 2002--In a move to better service its increasing customer base in Japan, Cyanotech Corporation (Nasdaq: CYAN) has formed a Japanese business unit, Cyanotech Japan YK, with an office in Tokyo. Through this unit, Cyanotech will be able to economize on shipping, provide more timely delivery to customers and allow customers to conduct business in Japanese Yen rather than US Dollars.

Cyanotech Japan will initially market NatuRose(R) and Spirulina Pacifica(R) to the Japanese animal feed market and later offer BioAstin(R) and Spirulina Pacifica to the human nutrition market. Current customers for animal feed products will transition to Cyanotech Japan by the end of March 2002.

Aquaculture feeding studies in Japan have shown that NatuRose is more effective than synthetic astaxanthin, particularly for species such as Sea Bream or "Tai," a major aquaculture product in Japan. NatuRose has also been shown to be very effective when used with other species of fish and land animals.

"The increasing acceptance of our products in one of the world's major economies caused us to form the new business unit," said Gerald R. Cysewski, Ph.D., chairman, president and CEO. "We are pleased to see this growing demand in the Japanese market, which holds significant potential for Cyanotech, particularly for our NatuRose product."

-- Cyanotech Corporation, the world's leader in microalgae technology, produces high-value natural products from microalgae, and is the world's largest commercial producer of natural astaxanthin (pronounced "asta-zan-thin") from microalgae. Products include BioAstin(R) natural astaxanthin, a powerful antioxidant with expanding applications as a human nutraceutical; NatuRose(R) natural astaxanthin for the aquaculture and animal feed industries; Spirulina Pacifica(R), a nutrient-rich dietary supplement; and phycobiliproteins, which are fluorescent pigments used in the immunological diagnostics market. Spirulina and BioAstin are sold directly online through www.nutrex-hawaii.com and through resellers worldwide. Corporate and product information is available at www.cyanotech.com

Penwest and Finzelberg to Jointly Develop and Market Herbal Formulations using Penwest’s Prosolv® Technology

Patterson, NY, and Andernach, Germany, January 24, 2002 - Penwest Pharmaceuticals Co. (NASDAQ: PPCO), a leader in innovative drug delivery technologies, and Finzelberg GmbH & Co. KG, a member of The Martin Bauer Group and a manufacturer of herbal extracts for the nutritional industry, today announced that they have agreed to jointly develop and market a new line of herbal supplement formulations utilizing Penwest’s PROSOLV® technology. The new line will be marketed to nutritional companies under the brand name RediRun DC™.

This collaboration will combine Penwest’s expertise in oral drug delivery and Finzelberg’s experience in producing herbal extracts to overcome typical challenges of manufacturing nutritional products. Nutritional actives often absorb moisture, flow poorly and are not compactable, resulting in bulky tablets or capsule formulations. Applying PROSOLV during the herbal extraction process solves these problems at the source and reduces the need for additional excipients and manufacturing processes. As a result, the RediRun DC™ formulations produce significantly smaller, lower cost tablets and improve patient compliance.

Stephen J. Berté, Jr., Senior Vice President and General Manager of Penwest, said, “We anticipate wide acceptance of the RediRun formulations, which can be extended to all herbal supplements. Independent research has demonstrated that nutritional manufacturers and consumers desire smaller, less expensive tablets and once-a-day dosing. RediRun effectively meets these needs of the nutritional market and we believe that this technology can also be successfully applied to pharmaceutical formulations.

“This alliance with Finzelberg also expands Penwest’s participation in PROSOLV drug development programs by patenting and co-marketing our formulated products. We are therefore applying the successful strategy from our TIMERx® joint development alliances to PROSOLV herbal formulations and will share the development and associated costs and profits with Finzelberg.”

Franz Meister, Chief Executive Officer of Finzelberg said, “The patented application of the PROSOLV technology delivers an exciting new product line to the nutritional industry, providing nutritional marketers with key advantages - a clearly differentiated product and early market entry by enabling immediate tablet production and eliminating bulky excipients, expensive processing and long formulation time.”

Allan Himmelstein, President of The Martin Bauer Group added, “Our collaboration with Penwest has already formulated Ginseng and St. John’s Wort products, which are two- to five-times smaller than traditional herbal supplements and we expect to introduce additional products within the year.”

About Penwest
Penwest is engaged in the research, development and commercialization of novel drug delivery technologies. Based on its experience in developing and manufacturing ingredients for orally administered pharmaceutical products, Penwest has developed its proprietary TIMERx® controlled release delivery and PROSOLV ® High Functionality Excipient technologies, which can be applied to a broad range of drugs.

About Finzelberg
Finzelberg GmbH, located in Andernach, Germany, produces herbal extracts for the pharmaceutical and dietary supplement industries. It is part of the Plantextrakt Holding GmbH & Co. in Vestenbergsreuth, Germany and is represented in the U.S. by The Martin Bauer Group of Parsippany, NJ.

Drawing on over 150 plant species, Finzelberg produces more than 1,000 different extracts. Its product range encompasses powdered and soft extracts including compacted granules for tablets and capsules.

Finzelberg follows the most stringent international quality standards from the preparation of raw materials through extraction and drying. The company uses digitally guided high tech facilities and equipment that adhere to DIN ISO 9001 regulations as well as GMP standards, also carefully protecting the biologically active plant constituents.

Raw materials are sourced from every climatic zone in the world and stored in extensive warehouse facilities to insure a steady supply.

Finzelberg has a history of over 125 years in the manufacture of healthful extracts.

The matters discussed herein contain forward-looking statements that involve risks and uncertainties, which may cause Penwest’s actual results in future periods to be materially different from any future performance suggested herein. For this purpose, any statements contained herein that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the foregoing, the words, “believes,” “anticipates,” “plans,” “expects,” “intends,” “potential,” and similar expressions are intended to identify forward-looking statements. Such risks and uncertainties include the need for the Company to raise capital in order to fund increasing R&D spending and the risk that Penwest will not be able to raise such funds or will only be able to raise such funds on unfavorable terms; dependence on collaborators to, among other things, sell products for which the Company receives royalties and advance clinical development and commercialization of products; the ability to enter into additional collaborations; uncertainty of success of collaborations; the risk of patent litigation; regulatory risks relating to TIMERx® drugs in development; the timing of clinical trials; actual and potential competition; the timing and outcome of regulatory approval of products and other risks as set forth under the caption “Risk Factors” in Penwest’s Current Report on Form 8-K, filed with the Securities and Exchange Commission on July 25, 2001, and which risk factors are incorporated herein by reference.

# # #

Journal of Internal Medical Research Publishes Fifth Study in 18 Months Showing CLA, Body Fat Reduction Connection

Vernon Hills, IL - The Journal of International Medical Research (2001: 29:392-296) has published a recent study presented by the Scandinavian Clinical Research AS, Kjeller, Norway, which demonstrates that conjugated linoleic acid (CLA) reduces body fat in humans. This is the fifth study published in a peer-reviewed medical journal within 18 months confirming CLA's role in body fat reduction. The CLA used in this study was Tonalin® CLA, which provides the highest activity available at 80 percent, and is only available from Natural Inc.

The randomized, double blind study comprised of 20 participants, ages 18 to 30, who were recruited from a physical fitness center where they engaged in regular physical training consisting of 90 minutes of strenuous exercise, three times a week. Volunteers were directed not to change their diet or lifestyle during the study. The study was conducted according to the current Declaration of Helsinki, Good Clinical Practice and local health regulations.

"Body fat, measured using near infrared light, was significantly reduced in the group taking CLA during the study," said Ola Gudmundsen, PhD, CEO of Scandinavian Clinical Research, and a co-author of the study. "This study shows those participants who ingested 1.8 grams of CLA per day experienced body fat reduction versus the placebo group. These results confirm a trend seen in several recent CLA studies and suggest the need for the continued study of CLA and its impact on humans."

Dr. Gudmundsen further indicated that while the observations recorded in the Scandinavian Clinical Research report are in accordance with other recent CLA study results, the effect obtained in this Norwegian research is much more pronounced than that previously reported.

According to Delbert Dorscheid, MD, PhD, University of British Columbia, "This recently published study in JIMR on the properties of CLA continues to demonstrate that CLA prevents fat from being deposited into the body. As it reduces body fat, it increases lean tissue. This action indirectly boosts a human's metabolism as lean tissue burns more calories than fatty tissue."

In several recent studies, CLA has received considerable attention due to its metabolic and chemoprotective properties in animals, as well as some similar, initial results in humans. The effects include reduced body fat content, improved serum lipid profiles, decreased aortic lipid deposition, and enhanced glucose metabolism.

Previously, a University of Wisconsin study concluded that subjects who stopped dieting and exercising regained less fat and retained more muscle mass when taking CLA versus those who had not. Another study published in The Journal of Nutrition (December 2000) found that without a change in exercise or diet, participants taking CLA experienced an average reduction of six pounds of body fat, compared with a placebo group. Last year, a study that appeared in The International Journal of Obesity (Volume 25, Issue 8, August 2001) showed that male subjects classified as abdominally obese lost an average of one inch from their waistlines in a four-week period when using CLA. Finally, a study that was published in Lipids (August 2001) found that of 53 patients, those taking CLA over the course of a 14-week trial experienced body fat reductions of 3.8 percent.

The CLA used in these studies was Tonalin®, manufactured by Natural Inc. Additional human studies on the body fat reduction aspects of CLA are underway and anticipated in the next year.

Tonalin® CLA has been available from Natural Inc., based in Vernon Hills, IL, since 1997. Tonalin® CLA has a history of safe and efficacious use, and is found in such U.S. product lines as Natrol, GNC, Your Life, EAS, Vitamin World, Nature's Way and Nature's Plus. Products containing Tonalin® CLA are available in supermarkets, drug stores, health food stores and from mass merchandisers nationwide. Tonalin® CLA is also distributed in Asia, Canada, France, Italy, Spain, Japan, the Scandinavian countries and the United Kingdom.

The Wisconsin Alumni Research Foundation (WARF), a not-for-profit organization, administers patents on the intellectual property for the faculty of the University of Wisconsin-Madison. WARF selected Natural ASA to produce and market CLA. Natural ASA holds multiple patents on CLA and supports continued research into the health benefits of this molecule.

Natural Inc. is a division of Natural ASA, a publicly-traded Norwegian company and a leader in the development of scientifically based ingredients for the worldwide nutrition industry. Natural Inc. exclusively markets and promotes Tonalin® CLA as a dietary supplement.

Margaret Anderson
ignite marketing group
480.592.9609
[email protected]
www.tonalin.com

Intramedicine, Inc. Licenses Science-Based, Clinical Information to Pharmavite Corp.

Westlake Village, Calif. - Intramedicine, Inc. (www.intramedicine.com), a leading health information publishing and new technology services company, announced today that it is licensing its consumer suite of science-based, clinical information to Pharmavite Corp. for use at the new Nature Made Wellness Advisor Web site (www.NatureMade.com).

Pharmavite Corp., founded in 1971, is a Northridge, CA corporation that was recently named "2001 Manufacturer of the Year" by Nutritional Outlook, a national trade publication. The Company manufactures Nature Made® vitamins and minerals, SAM-e, Nature's Resource® herbal products, Optimize™ fiber/calcium beverages, and other supplements designed to promote health. Now, through the Nature Made Wellness Advisor Web site, the Company will link to Intramedicine's broad database containing hundreds of consumer monographs on vitamins, minerals, herbs and nutraceuticals, as well as health condition information, containing reviews of scientific research in the field of integrative medicine. In addition, visitors to the sites will have access to a searchable drug/nutrient interactions and depletions database and a searchable archive of hundreds of articles pertaining to health and wellness.

"We are pleased to have been selected by, and be working with, a leader in the vitamin manufacturing industry," stated Jeffrey Eisenberg, CEO of Intramedicine, Inc. "We feel that our clinical information is on track with Pharmavite's online educational initiative which is to provide consumers with unbiased, science-based information in real time on health and wellness."

"Intramedicine's science-based content makes it easier than ever for consumers to access reliable health information online," said Barbara Lindquist, Nature Made senior product manager. "We're very excited to offer the Intramedicine database as additional content on our new Wellness Advisor site."

About Intramedicine, Inc.

Intramedicine, Inc. is a health information publishing and new technology services company, which has developed proprietary technology to manage and dynamically deliver vast content libraries to its end-users. The Company has executed the first phase of its business plan by developing the preeminent science-based information database in the field of integrative medicine, which, as a digital publisher, can be delivered online, via CD Rom, books, newsletters, continuing education or seminars. Intramedicine is currently the global source for integrative medical information for the healthcare, pharmaceutical, pharmacy, and natural product manufacturing industries. Intramedicine researches the full range of scientifically validated complementary and conventional medical therapies available throughout the world and provides clinical data in support of how these medical disciplines work best in synergy. Intramedicine is a content and technology Partner with the DSEA/DSIB. General information about Intramedicine is available at our web site at .

About Pharmavite

Founded in 1971, Northridge, California-based Pharmavite Corporation manufactures Nature Made® vitamins and minerals, SAM-e, Nature's Resource® herbal products, Optimize™ fiber/calcium beverages, and other supplements designed to promote health. Recently voted "Manufacturer of the Year" by the national trade publication Nutritional Outlook, and recipient of the 2001 Retail Excellence Award in the OTC-natural health category from Drug Industry News magazine, Pharmavite maintains one of the largest, most sophisticated research and development facilities in the industry and was instrumental in developing Good Manufacturing Practices (GMPs) for supplements. Pharmavite's facilities have been inspected and found to be in compliance with United States Pharmacopoeia's GMPs, the industry's most stringent standards.

Nature Made is America's number one, broadline brand of vitamins and minerals in the food, drug and mass channels. Several of its products carry the medical seal of acceptance from the American Medical Women's Association, the largest medical organization of woman physicians. Nature Made's newly launched Wellness Advisor (NatureMade.com), an online educational initiative, utilizes sophisticated analytical tools to provide consumers with personalized health tips and wellness solutions. Nature's Resource (www.NaturesResource.com) offers one of the nation's strongest herbal supplement education programs for consumers and medical professionals.

Elaine Roche
Marketing Director
Intramedicine, Inc.
790 Hampshire Rd. Suite H
Westlake Village, CA 91361
Ph (805) 373-8715
Fax (805) 371-9510
www.intramedicine.com

Perrigo Company Reports Second Quarter Fiscal 2002 Earnings of $0.22 Per Share

Source: PRNewswire

ALLEGAN, Mich., Jan. 23 /PRNewswire-FirstCall/ -- Perrigo Company (Nasdaq: PRGO) today announced results for the second quarter and six months ended December 29, 2001.

Net sales for fiscal 2002's second quarter increased 21 percent to $228.7 million from $189.6 million last year. In last year's second quarter, the Company complied with the Food and Drug Administration's (FDA) recommendation to discontinue production of cough and cold products and diet aids containing phenylpropanolamine (PPA). This action resulted in a $14.0 million reduction in sales and a charge to earnings of $24.0 million before tax, or $0.21 per share, for last year's second quarter. Sales in the current quarter increased 12 percent when compared with proforma sales prior to the PPA discontinuation of $203.6 million.

Net income for the quarter was $16.6 million, or $0.22 per share, which includes an after-tax charge of $1.2 million, or $0.02 per share, related to the bankruptcy announcement of a key customer. This compares with net income of $0.8 million, or $0.01 per share, in the second quarter of 2001. Net income last year prior to the PPA charge was $16.1 million, or $0.22 per share.

David T. Gibbons, President and Chief Executive Officer, stated, "We are pleased with second quarter revenues, operating expense control and earnings growth. Our inventory planning strategy enabled us to achieve our highest in- season customer service levels in years. Inventory availability and higher fill rates helped us take advantage of selling opportunities to achieve excellent results. The over-the-counter (OTC) pharmaceutical business drove double-digit sales growth with the cough and cold and gastrointestinal product categories recording strong gains. Sales also benefited from the incremental new business of famotidine tablets and ibuprofen cold and sinus tablets, new products launched within the past six months. Gross profit margin approximated last year despite recognizing the additional costs for quality and compliance and increased inventory reserves.

"During the quarter, we received regulatory approval for two new products," noted Gibbons. "In December, the FDA granted approval to manufacture and market OTC tioconazole ointment and migraine formula tablets. We expect to be first to market with these important additions to the feminine hygiene and analgesic product categories when they begin shipping in the second half."

Fiscal 2002's first-half sales were $445.8 million, up 17 percent from $381.7 million reported last year. Net sales prior to the product discontinuation were $395.7 million. Net income for the six months was $29.7 million, or $0.39 per share, which includes an after-tax charge of $1.2 million, or $0.02 per share, related to the bankruptcy announcement of a key customer. This compares with net income of $11.4 million, or $0.15 per share, a year ago. Net income for six months last year before the PPA charge was $26.7 million, or $0.36 per share.

Commenting on the outlook for the second half, Mr. Gibbons stated, "We have seen a slower-than-forecasted cold and flu season to this point and we have taken action to manage inventories accordingly. With the second quarter charge of $0.02 per share, we are comfortable with earnings between $0.58 and $0.60 per share for the full year."

The Company also announced that during the quarter, it sold the LaVergne, Tennessee distribution center for $14.2 million and repurchased 644,000 shares for $8.2 million under its common stock repurchase program.

Perrigo will host a conference call to discuss second quarter fiscal 2002 results at 11:00 a.m. (EST) today. The call and replay will be available via webcast on the Company's web site at www.perrigo.com . The conference call may also be accessed by phone on a listen-only basis by calling 1-877-209-9921 and asking for Perrigo's second quarter review. A taped replay of the call will be available beginning at approximately 2:30 p.m. (EST) Wednesday, January 23. To listen to the replay, call 1-800-475-6701, access code 624157 (outside the United States, call 320-365-3844).

Perrigo Company is the nation's largest manufacturer of over-the-counter (non-prescription) pharmaceutical and nutritional products sold by supermarket, drug, and mass merchandise chains under their own labels. The Company's products include over-the-counter pharmaceuticals such as analgesics, cough and cold remedies, gastrointestinal, and feminine hygiene products, and nutritional products, such as vitamins, nutritional supplements and nutritional drinks. Visit Perrigo on the Internet at http://www.perrigo.com .

Note: Certain statements in this press release are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and are subject to the safe harbor created thereby. Please see the "Cautionary Note Regarding Forward-Looking Statements" on pages 24-29 of the Company's Form 10-K for the year ended June 30, 2001 for a discussion of certain important factors that relate to forward-looking statements contained in this press release. In addition, the Company's future results may be affected by the impact of events flowing from the September 11, 2001 terrorist attacks, current economic conditions in the United States, retailers' financial difficulties or current cough/cold/flu seasonal trends. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, it can give no assurance that such expectations will prove to be correct. Unless otherwise required by applicable securities laws, the Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Chemi Sponsors Presentation at Nutritionals 2002

White Bear Lake, MN-Chemi Nutra is sponsoring a presentation at the Nutritionals 2002 Symposium, February 5 - 7, 2002 at the Anaheim Convention Center in Anaheim, California. The program, entitled "IronAid™ Iron Protein Succinylate (IPS): An Advancement in the Treatment of Iron Deficiency and Anemia, will be delivered by Thomas Incledon on February 6 from 1:30 - 2:00 PM.

IronAid™, a patented, proprietary form of iron, was developed through innovative technology. When compared to conventional forms of iron, IronAid™ demonstrates improved absorption, tolerability, and efficacy. Because IronAid™ is insoluble in the stomach; it does not cause gastric disturbances like conventional forms of iron. IronAid™ has been subjected to numerous clinical studies for safety and efficacy and has been used by over 3,000,000 people with iron deficiency.

THOMAS INCLEDON, MS, RD, LD, LN, NSCA-CPT, CSCS, is a PhD candidate in Exercise Physiology at the University of Miami. He serves as an adjunct faculty member at both Nova Southeastern University and Florida Atlantic University. Tom has degrees in Management, Exercise and Sport Science, Nutrition, and Kinesiology. He has received several awards and fellowships for his academic achievements. He is a licensed nutritionist and dietitian in the state of Florida, and is president of the Incledon Wellness Institute, a nonprofit research center, and serves as a consultant to several nutraceutical companies.

Chemi Nutra is the new US branch of parent company Chemi S.p.A., a privately held pharmaceutical and nutraceutical company based in Milan, Italy. Chemi, with cGMP certified manufacturing facilities in Italy and Brazil, is best known in the US nutritional arena for its introduction of phosphatidyl serine (PS), the popular dietary supplement to enhance memory, and other specialty nutritional ingredients.

NBTY Reports Record First Quarter Sales & Net Income Wholesale Sales Up 66%

BOHEMIA, N.Y., Jan. 23 -- NBTY, Inc. (Nasdaq: NBTY) (http://www.NBTY.com), a leading manufacturer and marketer of nutritional supplements, today announced results for the fiscal first quarter ended December 31, 2001.

For the first quarter ended December 31, 2001, net sales increased 29% to $215 million from net sales of $167 million for the first quarter last year. Net income for the first quarter increased to $11 million, or $0.17 per diluted share compared to net income of $639 thousand, or $0.01 per diluted share for the first quarter last year.

Results for the first quarter reflect an increase in sales generated in all areas of the Company's operations, the most significant of which occurred in the Company's wholesale division.

The Company continues to maintain its financial strength. Working capital increased $8 million to approximately $139 million at December 31, 2001 compared with $131 million at September 30, 2001. Since September 30, 2001 the Company has: reduced bank debt by over $8 million; lowered total liabilities by approximately $22 million; and reduced inventories by $9 million. Overall gross profit was 53.1% for the first quarter ended December 31, 2001 compared with 55.3% for the prior like quarter reflecting increased sales for the wholesale division which traditionally has a lower gross profit. Without Global Health Sciences (acquired May 2001), gross profit would have been approximately 56%.

Operations

Sales for the Nature's Bounty wholesale operation were $66 million compared with $40 million the previous like quarter, an increase of approximately 66%. Of the $26 million increase, approximately $15 million was attributable to newly acquired businesses. The balance reflects an increase in the sales of core products and strong sales response to new product introductions and promotions. The Company's Flex-A-Min product has maintained its broad distribution since its successful advertising campaign in the first quarter of last year. The Company's newly-acquired Knox NutraJoint and Knox for Nails nutritional supplement business from Kraft Foods has broadened the product base and has given the Company entree to new wholesale accounts.

Global Health Sciences, acquired last fiscal year, has increased the Company's manufacturing capacity and was profitable for the quarter ended December 31, 2001. The Company now has manufacturing facilities in New York, New Jersey, Illinois, Colorado and California. With these five locations, the Company has a competitive advantage by being closer to its wholesale customers and thus can give better service.

While industry sales have stagnated, thereby burdening competitor companies, NBTY has increased its market share in mass market and chain drug retailers. By utilizing consumer sales information received from its Vitamin World and direct response/e-commerce operations, the Company has been able to provide its mass-market customers with tools to drive sales. The Company continues to respond to consumer preferences and monitor the market for trends and ideas, which translate into increased sales for the mass market. The Nature's Bounty brand is now recognized for its ability to generate greater sales than competing brands. The Company continues to focus its energies in gaining market share in this sector.

Vitamin World currently operates 533 stores nationwide; sales increased 14.1% from the prior like period, and same store sales increased 6.1%. While this operation is still not profitable, losses before corporate overhead allocations have been reduced by 70%. Holland & Barrett sales increased 19.8% as it continues to be a leader in the U.K. market with same store sales up 11.5%. New customers from acquired mail order and Internet companies during fiscal year 2001 contributed sales of approximately $8 million for the quarter. These operations have been fully integrated into the Company's ongoing direct response/e-commerce operations.

SUMMARY

NBTY Chairman and Chief Executive Officer Scott Rudolph stated, "We are gratified that our focus and commitment to the wholesale business has contributed substantially to the overall rise in first quarter revenues. We continue to look for additional ways to increase our market share in this sector and to better serve our customers. The Company will strive to maintain its leadership position in the marketing of nutritional supplements and we remain optimistic for the long-term outlook for the Company." ABOUT NBTY
NBTY is a leading vertically integrated U.S. manufacturer and distributor of a broad line of high-quality, value-priced nutritional supplements in the United States and throughout the world. The Company markets more than 1,500 products under several brands, including Nature's Bounty(R), Vitamin World(R), Puritan's Pride(R), Holland & Barrett(R), Nutrition Headquarters(R), American Health(R), Nutrition Warehouse(R) and Dynamic Essentials(R).

This release contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 with respect to our financial condition, results of operations and business. All of these forward-looking statements, which can be identified by the use of terminology such as "subject to," "believe," "expects," "may," "will," "should," "can," or "anticipates," or the negative thereof, or variations thereon, or comparable terminology, or by discussions of strategy which, although believed to be reasonable, are inherently uncertain. Factors that may affect such forward- looking statements include (i) slow or negative growth in the nutritional supplement industry; (ii) disruptions of business or negative impact on sales and earnings due to acts of war, terrorism, bio-terrorism, or civil unrest; (iii) adverse publicity regarding the consumption of nutritional supplements; (iv) inability to retain customers of companies (or mailing lists) recently acquired; (v) increased competition; (vi) increased costs; (vii) loss or retirement of key members of management; (viii) increases in the cost of borrowings and unavailability of additional debt or equity capital; (ix) unavailability of, or inability to consummate, advantageous acquisitions in the future or the inability of the Company to assimilate acquisitions into the mainstream of its business; (x) changes in general worldwide economic and political conditions in the markets in which the Company may compete from time to time; (xi) the inability of the Company to gain and /hold market share of its wholesale and retail customers; (xii) unavailability of electricity in certain geographical areas; (xiii) exposure to, expense of defending and resolving, product liability claims and other litigation; (xiv) the ability of the Company to successfully implement its business strategy; (xv) the inability of the Company to manage its retail operations efficiently; (xvi) consumer acceptance of the Company's products; (xvii) uncertainty in negotiating and consummating acquisitions which may be subject to bankruptcy court approval; (xviii) the inability of the Company to renew leases on its retail locations; (xix) inability of the Company's retail stores to attain profitability; (xx) the absence of clinical trials for many of the Company's products; (xxi) sales and earnings volatility; (xxii) the Company's ability to manufacture its products efficiently; (xxiii) the rapidly changing nature of the Internet and on-line commerce; (xxiv) fluctuations in foreign currencies, and more particularly the British Pound; (xxv) import-export controls on sales to foreign countries; (xxvi) the inability of the Company to secure favorable new sites for, and delays in opening, new retail locations; (xxvii) adverse federal, state or foreign legislation or regulation or adverse determinations by regulators; (xxviii) the mix of the Company's products and the profit margins thereon; (xxix) the availability and pricing of raw materials; (xxx) factors discussed in the Company's filings with the Securities and Exchange Commission; and (xxxi) other factors beyond the Company's control.

ABC, AHPA, NNFA endorse SupplySide Asia 2002

PHOENIX--Virgo Publishing announced that the SupplySide Asia 2002 trade show and conference is being endorsed by the American Botanical Council (ABC), American Herbal Products Association (AHPA), and the National Nutritional Foods Association (NNFA). SupplySide Asia is scheduled for Sept. 4-6, 2002, at the Pacifico Convention Center in Yokohama, Japan.

“The endorsement by these organizations will add to the broad support that SupplySide Asia is experiencing in both the U.S. and Japan,” said Jon Benninger, group publisher at Virgo Publishing. “We anticipate similar support from organizations in Japan and Asia.”

In addition to offering their support, each of the endorsing organizations will assist with development of the SupplySide Asia seminar program. Confirmed speakers include NNFA Executive Director David Seckman, AHPA Executive Director Michael McGuffin, and ABC Chief Administrative Officer Wayne Silverman, Ph.D.

“This is a good opportunity for the herbal products industry to meet in the growing Asian market during an important point in its development,” McGuffin said. “AHPA and its members will benefit by participating.”

“Virgo has consistently shown leadership by providing venues and experiences that meet the needs of the those in the natural products movement,” Silverman said. “ABC, an independent educational organization, is pleased to join with industry associations in sponsoring and supporting this first SupplySide Asia."

"NNFA has been instrumental in the establishment of a more favorable regulatory climate for dietary supplements in Japan,” Seckman said. “ In fact, NNFA-Japan, which was established in 1998, is the only foreign offshoot of the U.S. NNFA. SupplySide Asia offers an opportunity for further industry exposure and expansion in Japan and underscores these efforts. A strategic alliance with Virgo Publishing in support of SupplySide Asia is a logical extension of our long-term commitment to facilitating trade with Japan on behalf of our members and the industry."

SupplySide Asia is organized by U.S.-based Virgo Publishing Inc. and Tokyo-based International Nutraceutical Network Inc. Virgo Publishing produces leading business magazines for the health food and nutrition industry in the United States, as well as the popular SupplySide East and SupplySide West trade shows. INNI works with top U.S. and Japanese companies to assist with international business development. SupplySide Asia is co-organized by Kenkosanyoriutsu Shinbun, a leading industry journal in Japan.

SupplySide Asia will bring together leading manufacturers, suppliers and distributors from the health and nutrition industry to explore international business opportunities. The event includes an international exhibit hall, a complete seminar program and networking receptions all designed to bring together top companies from the United States, Europe, Asia and South America.

Additional services include simultaneous translation of all seminars, pre-set meetings for exhibitors, pre-event training in Japanese business customs, and assistance with follow-up.

“We intend to provide our exhibitors and attendees with service and assistance that is unprecedented,” said Benninger. “Our goal is to ensure that each and every participant finds success and opportunity at this event.”

Information about exhibiting, sponsoring or speaking is available by contacting Todd Willis at (480) 990-1101, ext. 1171 or at [email protected]